IRL-003 + NWY-007

IRL-003 + NWY-007 is a combination therapy or a dual-coded targeted therapy currently in Phase 1 development for oncology. Developed by Pierre Fabre Médicament, likely in partnership with a biotechnology firm (potentially Newave Pharmaceutical, given the 'NWY' prefix), the drug is designed as a targeted therapy for solid tumors. While specific molecular targets for the NWY-007 component are not publicly disclosed in the provided pipeline excerpts, the 'IRL' prefix is characteristic of Pierre Fabre's internal research codes (Institut de Recherche Pierre Fabre). The therapy is part of a broader oncology portfolio that includes other targeted agents such as SHP2 inhibitors and RAF inhibitors.